Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Oryzon Genomics (ORY SM)
Watchlist
54
Analysis
Health Care
•
Spain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Oryzon Genomics
•
02 Aug 2024 01:10
•
Issuer-paid
Oryzon Genomics - Multiple milestones anticipated in H224
Oryzon’s Q224 results summarised an active quarter for its clinical pipeline, with multiple milestones expected in H224. Central to the H224...
Edison Investment Research
Follow
150 Views
Share
bullish
•
Oryzon Genomics
•
09 Jul 2024 19:10
•
Issuer-paid
Oryzon Genomics - Strengthening vafidemstat’s IP profile
Oryzon Genomics continues to fortify its IP profile for vafidemstat, which is being developed for borderline personality disorder (BPD) and for the...
Edison Investment Research
Follow
156 Views
Share
bullish
•
Oryzon Genomics
•
14 Jun 2024 19:10
•
Issuer-paid
Oryzon Genomics - Encouraging interim update on FRIDA
Oryzon Genomics has reported positive interim data from the Phase Ib FRIDA study, evaluating iadademstat in combination with gilteritinib in...
Edison Investment Research
Follow
189 Views
Share
bullish
•
Oryzon Genomics
•
05 Jun 2024 07:10
•
Issuer-paid
Oryzon Genomics - ALICE data published in The Lancet Haematology
Oryzon Genomics has announced the publication of the final ALICE trial results in the recognised peer-reviewed journal The Lancet Haematology. The...
Edison Investment Research
Follow
223 Views
Share
bullish
•
Oryzon Genomics
•
30 May 2024 19:10
•
Issuer-paid
Oryzon Genomics - EC taps Oryzon for healthcare initiative
The European Commission has selected Oryzon to support a new healthcare initiative furthering innovation in the region. As an associated partner of...
Edison Investment Research
Follow
240 Views
Share
1
2
3
4
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x